FDA grants approval for bluebird’s Zynteglo to treat beta-thalassemia
Pharmaceutical Technology
AUGUST 18, 2022
The US Food and Drug Administration (FDA) has granted approval for bluebird bio ’s Zynteglo (betibeglogene autotemcel, beti-cel) for the treatment of the underlying genetic cause of beta?thalassemia 0 genotypes. thalassemia in adult and paediatric patients.
Let's personalize your content